Literature DB >> 10933308

Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats.

K A Al-Barazanji1, J R Arch, R E Buckingham, M Tadayyon.   

Abstract

OBJECTIVE: To investigate whether chronic administration of the long-acting glucagon-like peptide-1 receptor agonist exendin-4 can elicit sustained reductions in food intake and body weight and whether its actions require an intact leptin system. RESEARCH METHODS AND PROCEDURES: Male lean and obese Zucker (fa/fa) rats were infused intracerebroventricularly with exendin-4 using osmotic minipumps for 8 days.
RESULTS: Exendin-4 reduced body weight in both lean and obese Zucker rats, maximum suppression being reached on Day 5 in obese (8%) and Day 7 in lean (16%) rats. However, epididymal white adipose tissue weight was not reduced, and only in lean rats was there a reduction in plasma leptin concentration. Food intake was maximally suppressed (by 81%) on Day 3 in obese rats but was reduced by only 18% on Day 8. Similarly, in lean rats food intake was maximally reduced (by 93%) on Day 4 of treatment and by 45% on Day 8. Brown adipose tissue temperature was reduced from Days 2 to 4. Plasma corticosterone was elevated by 76% in lean but by only 28% in obese rats. DISCUSSION: Chronic exendin-4 treatment reduced body weight in both obese and lean Zucker rats by reducing food intake: metabolic rate was apparently suppressed. These effects did not require an intact leptin system. Neither does the absence of an intact leptin system sensitize animals to exendin-4. Partial tolerance to the anorectic effect of exendin-4 in lean rats may have been due to elevated plasma corticosterone and depressed plasma leptin levels, but other counter-regulatory mechanisms seem to play a role in obese Zucker rats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933308     DOI: 10.1038/oby.2000.38

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  8 in total

Review 1.  GLP-1 and energy balance: an integrated model of short-term and long-term control.

Authors:  Jason G Barrera; Darleen A Sandoval; David A D'Alessio; Randy J Seeley
Journal:  Nat Rev Endocrinol       Date:  2011-06-07       Impact factor: 43.330

Review 2.  Drug treatment of obesity.

Authors:  G A Bray
Journal:  Rev Endocr Metab Disord       Date:  2001-10       Impact factor: 6.514

Review 3.  Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes.

Authors:  Teresa Salvatore; Raffaele Galiero; Alfredo Caturano; Erica Vetrano; Luca Rinaldi; Francesca Coviello; Anna Di Martino; Gaetana Albanese; Sara Colantuoni; Giulia Medicamento; Raffaele Marfella; Celestino Sardu; Ferdinando Carlo Sasso
Journal:  Biomolecules       Date:  2022-01-21

4.  A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.

Authors:  Victor A Gault; Vikas K Bhat; Nigel Irwin; Peter R Flatt
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

5.  Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.

Authors:  Olivia M Farr; Michael A Tsoukas; Georgios Triantafyllou; Fadime Dincer; Andreas Filippaios; Byung-Joon Ko; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-03-18       Impact factor: 8.694

6.  Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats.

Authors:  Roger D Reidelberger; Alvin C Haver; Prasanth K Chelikani; James L Buescher
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-06-11       Impact factor: 3.619

7.  Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice.

Authors:  Sander Kooijman; Yanan Wang; Edwin T Parlevliet; Mariëtte R Boon; David Edelschaap; Gido Snaterse; Hanno Pijl; Johannes A Romijn; Patrick C N Rensen
Journal:  Diabetologia       Date:  2015-08-09       Impact factor: 10.122

Review 8.  Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review.

Authors:  Michał Konwerski; Aleksandra Gąsecka; Grzegorz Opolski; Marcin Grabowski; Tomasz Mazurek
Journal:  Biology (Basel)       Date:  2022-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.